The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2019

Filed:

Oct. 30, 2018
Applicants:

Medizinische Universitat Wien, Vienna, AT;

Universitatsklinikum Freiburg, Freiburg, DE;

Inventors:

Christian Werner Gruber, Klosterneuburg, AT;

Carsten Gruendemann, Freiburg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/16 (2006.01); A61K 38/12 (2006.01); C07K 14/415 (2006.01); A61K 45/06 (2006.01); A61K 51/08 (2006.01); C07K 14/00 (2006.01); G01N 33/50 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/168 (2013.01); A61K 38/12 (2013.01); A61K 38/16 (2013.01); A61K 45/06 (2013.01); A61K 51/08 (2013.01); A61P 37/06 (2018.01); C07K 14/00 (2013.01); C07K 14/415 (2013.01); G01N 33/5023 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. The present invention further relates to a method of screening for and/or selecting an immunosuppressive cyclotide or a mutation which results in a mutated cyclotide having an induced or enhanced immunosuppressive activity. The present invention further relates to a method of producing an immunosuppressive cyclotide or an immunosuppressive pharmaceutical composition. The present invention further relates to a mutated cyclotide having immunosuppressive activity and a pharmaceutical composition comprising the same.


Find Patent Forward Citations

Loading…